Poolbeg Pharma PLC (LON:POLB – Get Free Report)’s share price hit a new 52-week low on Wednesday . The stock traded as low as GBX 6.96 ($0.09) and last traded at GBX 7.14 ($0.09), with a volume of 463643 shares traded. The stock had previously closed at GBX 7.20 ($0.09).
Poolbeg Pharma Price Performance
The firm has a 50 day simple moving average of GBX 7.96 and a 200-day simple moving average of GBX 10.79. The company has a market cap of £35.70 million, a price-to-earnings ratio of -714.00 and a beta of 2.11.
About Poolbeg Pharma
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.
Featured Stories
- Five stocks we like better than Poolbeg Pharma
- What does consumer price index measure?
- The Great CPU Race: AMD and Intel Battle for Dominance
- What is an Earnings Surprise?
- GameStop Turns a Profit: So What? It’s Still Not Worth Investing
- Learn Technical Analysis Skills to Master the Stock Market
- C3.ai Stock Surges on Strong Sales Despite Profit Concerns
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
